Barclays raised the firm’s price target on Ligand (LGND) to $150 from $125 and keeps an Overweight rating on the shares following the “beat and raise” quarter. The company’s outlook reflects strong performance across its three core revenue streams, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.